NeoLAB® Solid Tumor Liquid Biopsy Testing

Cell-free DNA analysis for solid tumor cancers

NeoLAB® Solid Tumor Liquid Biopsy is a next-generation sequencing assay for pan-cancer that includes 44 genes involved in solid tumor development and progression. This panel provides broad coverage of actionable markers supported by clinical guidelines and on-going clinical trials.

Biomarkers detected are implicated in a variety of tumor types including bladder, brain/CNS, breast, cervical, colorectal, endometrial, esophageal, gastric, head and neck, kidney, liver, lung, melanoma, ovarian, pancreatic, prostate, stomach, and thyroid.


Clinical applications:

  • Identifying targetable alterations to guide treatment decision
  • Monitoring disease status
  • Detecting potential resistance to therapy and its cause


NeoLAB® Solid Tumor Liquid Biopsy detects >900 hotspot SNVs and indels across 44 genes


Genes Investigated in the NeoLAB® Solid Tumor Liquid Biopsy

AKT1ERBB3HRASNTRK3
ALKESR1IDH1PDGFRA
APCFBXW7IDH2PIK3CA
ARFGFR1KITPTEN
ARAFFGFR2KRASRAF1
BRAFFGFR3MAP2K1RET
CHEK2FGFR4MAP2K2ROS1
CTNNB1FLT3METSF3B1
DDR2GNA11MTORSMAD4
EGFRGNAQNRASSMO
ERBB2GNASNTRK1TP53

Analytic validation demonstrated

Limit of Detection (LoD) = 0.1% allele fraction for indels, 0.15% for SNV.

98.0%

ACCURACY

95.1%

SENSITIVITY

98.8%

SPECIFICITY

Results are returned within 7 calendar days after sample is received.